Dragonfly AI Lands £3m to Expedite Global Expansion
12.4.2022 14:19:00 EEST | Business Wire | Press release
Dragonfly AI, the market leading predictive visual analytics platform, announced today that it has closed a £3m Series A funding round led by Guinness Ventures and existing investors Downing Ventures, while Capita PLC also participated in the round.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220412005628/en/
Dragonfly AI (Photo: Business Wire)
Dragonfly AI has seen rapid growth in its customer portfolio which includes over 50 global brands including Diageo, GSK, and Vodafone. The new investment allows Dragonfly AI to further scale up its sales engine, build the client growth team and invest in an exciting behavioural science, R&D and product development roadmap. The funds will also be used to accelerate international expansion plans across Europe and North America.
Co-founded in 2018, by entrepreneurs Mark Bainbridge and David Mitchell, Dragonfly AI helps brands improve creative performance by accurately and instantly predicting what your audience sees first across any content, any channel.
Using the power of artificial intelligence and cutting-edge neuroscience technology, the easy -to-use technology provides real-time actionable insights, that helps marketers and insight teams make data-informed decisions, resulting in better informed creative decisions, performance marketing and improved sales performance.
Richard Mann, Chief Executive Officer at Dragonfly AI said: “We’re delighted to close this round of funding from investors that share our vision for the value that predictive technologies can bring to the creative design process. The investment will allow Dragonfly AI to continue scaling-up across Europe and the US. It will also allow us to invest more heavily in our technology platform, including initiatives such as the new e-commerce benchmarks that we are launching this quarter.”
Shane Gallwey, Head of Guinness Ventures said: “Dragonfly’s predictive visual tools are best in class, which is why leading global brands already use the technology to optimise their marketing. Our investment into Dragonfly brings another gem to the Guinness portfolio and we look forward to supporting their success as they scale-up their business.”
Richard Lewis, Partner at Downing Ventures said: “We are thrilled to be supporting Dragonfly in the next stage of its growth journey. It is a privilege to continue to support entrepreneurial teams that have developed world-class, innovative technology here at Downing. We look forward to continuing the good work with Dragonfly and assisting with its international expansion.”
Matt Bunn, Co-Founder and Managing Director at Capita Scaling Partner, added: “This represents a fantastic milestone for Dragonfly, and we are delighted to continue our support for the business. The company is on an exciting growth trajectory and continues to develop its world-leading product. We are looking forward to working closely with Guinness, Downing and the Dragonfly team to further expand its international client base.”
*Press Release Ends*
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220412005628/en/
Contact information
Kassandra McCalla
kassandra.mccalla@dragonflyai.co
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 04:00:00 EEST | Press release
Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe ’s Coverage of ESCMID Global Congress 202617.7.2026 04:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 01:00:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-treat, high-impact sites, including the scalp, nails, palms and soles, compared with placebo.1-5 These data build on the topline results from the Phase 3 randomized, multicenter, double-blind, placebo- and active comparator-controlled LATITUDE PsO 3001 and 3002 studies.2,6 In those studies, about 70% of patients treated with zasocitinib achieved static Physician Global Assessment (sPGA) 0/1 (clear or almost clear skin) at week 16, with a significantly greater Psoriasis Area and Severity Index (PASI) 75 response rate seen as early as w
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance17.7.2026 00:36:00 EEST | Press release
The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful placement, Merz has further diversified its funding base by
The Estée Lauder Companies Appoints Madeleine Boyd as Senior Vice President, Global Brand Communications16.7.2026 23:22:00 EEST | Press release
The Estée Lauder Companies Inc. (NYSE: EL) today announced the appointment of Madeleine Boyd as Senior Vice President, Global Brand Communications, effective July 20, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716738393/en/ Photo by Esteban La Tessa As part of the company’s continued efforts to strengthen how its brands better connect with consumers, Ms. Boyd will establish and lead a newly integrated Global Brand Communications team. In this role, she will ensure the company’s diverse portfolio is anchored by a cohesive enterprise communications strategy, while accelerating bold, consumer-first storytelling that drives earned media, cultural relevance, and brand desirability. She will also strengthen creator engagement, helping the company’s brands gain attention where culture is being shaped. Ms. Boyd brings extensive experience spanning brand strategy, communications, consumer engagement, and cultural insight
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom